Microbiological profile of telithromycin, the first ketolide antimicrobial

Clinical Microbiology and Infection

Volumn 7, Issue SUPPL. 3, 2001, Pages 2-10

  Felmingham, D ^a  

^a GR Micro Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; KETOLIDE; MACROLIDE; TELITHROMYCIN;

CHLAMYDOPHILA PNEUMONIAE; COMPARATIVE STUDY; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE COCCI; HAEMOPHILUS INFLUENZAE; HUMAN; LEGIONELLA PNEUMOPHILA; MICROBIOLOGICAL EXAMINATION; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; CHLAMYDOPHILA PNEUMONIAE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE COCCI; HAEMOPHILUS INFLUENZAE; HUMANS; KETOLIDES; LEGIONELLA PNEUMOPHILA; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; MYCOPLASMA PNEUMONIAE; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 17344380498     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2001.00048.x     Document Type: Article

References (17)

1. Felmingham D, Grüneberg RN, and the Alexander Project Group. The Alexander Project 1996-97: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191-203.
2. Chen DK, McGreer A, De Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-9.
3. Davies TA, Kelly LM, Jacobs MR, Appelbaum PC. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test and disk diffusion methodologies. J Clin Microbiol 2000; 38: 1444-8.
4. Felmingham D, Robbins MJ, Leakey A et al. The comparative in vitro activity of HMR 3647, a ketolide antimicrobial, against clinical bacterial isolates. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 28 September-1 October, 1997. Washington DC: American Society for Microbiology, 2000, abstract F166.
5. Credito KL, Ednie LM, Jacobs MR, Appelbaum PC. Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology. Antimicrob Agents Chemother 1999; 43: 2027-31.
6. Ball P. Therapy for pneumococcal infection at the millennium: doubts and certainties. Am J Med 1999; 107: 77-85.
7. Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin- and erythromycin-susceptible and resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother 1998; 42: 624-30.
8. Dubois J, St Pierre C. In vitro activity of telithromycin, macrolides and quinolones against respiratory tract pathogens. In: Abstracts of the 40th Interscience Congress on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, 17-20 September 2000. Washington: DC: American Society for Microbiology, 2000: 178, abstract 2152.
9. Descheemaeker P, Chapeele S, Lammens C et al. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J Antimicrob Chemother 2000; 45: 167-73.
10. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991; 35: 1267-72.
11. Tait-Kamradt A, Clancy J, Cronan M et al. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41: 2251-5.
12. Otsuki M, Harada H, Nishino T. In vitro antibacterial activity of HMR 3647, a new ketolide antibiotic [Abstract E137]. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 24-27 September, 1998. Washington DC: American Society for Microbiology, 2000.
13. Felmingham D, Clark S, Robbins MJ, Dencer C, Bryskier A. In vitro bactericidal activity of HMR 3647 against respiratory tract pathogens. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 24-27 September 1998. Washington DC: American Society for Microbiology, 2000: 207, abstract E133.
14. Agouridas C, Bonnefoy A, Chantot JF. In vivo antibacterial activity of HMR 3647, a novel ketolide highly active against respiratory pathogens [Abstract 1.11]. In: Prog. 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides, 21-23 January 1998, Barcelona, Spain.
15. B resistance phenotype. J Antimicrob Chemother 1997; 40: 85-90.
16. Bonnefoy A, Agouridas C, Chantot JF. HMR 3647: antibacterial activity of resistance [Abstract 1.24]. In: Prog. 4th International Conference on the Macrolides, Azalides, Streptogramins and Ketolides, 21-23 January 1998, Barcelona, Spain.
17. Douthwaite S, Hansen LH, Mauvais P. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol Microbiol 2000; 36: 185-93.